NASDAQ:RVMD Revolution Medicines (RVMD) Stock Forecast, Price & News $24.53 -1.64 (-6.27%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$24.14▼$26.2950-Day Range$24.53▼$35.0552-Week Range$17.47▼$35.50Volume4.14 million shsAverage Volume1.44 million shsMarket Capitalization$2.68 billionP/E RatioN/ADividend YieldN/APrice Target$35.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Revolution Medicines MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside45.0% Upside$35.57 Price TargetShort InterestBearish12.03% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment-0.23Based on 3 Articles This WeekInsider TradingSelling Shares$3.74 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.46) to ($3.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector614th out of 965 stocksBiological Products, Except Diagnostic Industry88th out of 157 stocks 3.4 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.57, Revolution Medicines has a forecasted upside of 45.0% from its current price of $24.53.Amount of Analyst CoverageRevolution Medicines has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.03% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Revolution Medicines has recently increased by 1.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 2.1 News and Social Media Coverage News SentimentRevolution Medicines has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Revolution Medicines this week, compared to 2 articles on an average week.Search Interest8 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,739,912.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Revolution Medicines is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to grow in the coming year, from ($3.46) to ($3.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -7.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -7.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Revolution Medicines (NASDAQ:RVMD) StockRevolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More RVMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Stock News HeadlinesOctober 3, 2023 | americanbankingnews.comJeff Cislini Sells 2,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockSeptember 28, 2023 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) vs. Adaptimmune Therapeutics (NASDAQ:ADAP) Critical AnalysisOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 25, 2023 | msn.comRevolution Medicines: A Big Pipeline In Need Of Big DataSeptember 24, 2023 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Shares Down 2.2% September 21, 2023 | markets.businessinsider.comStifel Maintains Buy Rating for Revolution Medicines: Here's What You Need To KnowSeptember 20, 2023 | finance.yahoo.comInsider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD)September 19, 2023 | finance.yahoo.comRevolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) InhibitorOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.August 17, 2023 | finance.yahoo.comRevolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) ProteinsAugust 9, 2023 | finance.yahoo.comIndustry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue ForecastsAugust 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate ProgressAugust 9, 2023 | msn.comNeedham Maintains Revolution Medicines (RVMD) Buy RecommendationAugust 5, 2023 | benzinga.comLifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETAAugust 3, 2023 | finance.yahoo.comRevolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023August 1, 2023 | msn.comRevolution Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&DAugust 1, 2023 | markets.businessinsider.comRevolution Medicines To Acquire EQRx In All-Stock Transaction To Gain Over $1B In Additional CapitalAugust 1, 2023 | businesswire.comRVMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Revolution Medicines, Inc. Is Fair to ShareholdersJuly 11, 2023 | seekingalpha.comRevolution Medicines: Early-Stage Firm Whose High Valuation I Cannot ExplainJuly 6, 2023 | finance.yahoo.comRevolution Medicines Insider Ups Holding During YearJune 30, 2023 | fool.comRevolution Medicines (NASDAQ: RVMD)June 9, 2023 | finance.yahoo.comWe're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn RateMay 24, 2023 | finance.yahoo.comRevolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation SummitMay 13, 2023 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25%May 10, 2023 | finance.yahoo.comRevolution Medicines First Quarter 2023 Earnings: Beats ExpectationsMay 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate ProgressMay 9, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Revolution MedicinesSee More Headlines Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address RVMD Company Calendar Last Earnings8/08/2023Today10/03/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees292Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.57 High Stock Price Forecast$47.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+45.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-248,710,000.00 Net Margins-1,003.36% Pretax Margin-1,004.78% Return on Equity-36.46% Return on Assets-31.31% Debt Debt-to-Equity RatioN/A Current Ratio11.81 Quick Ratio11.81 Sales & Book Value Annual Sales$35.38 million Price / Sales75.69 Cash FlowN/A Price / Cash FlowN/A Book Value$7.72 per share Price / Book3.18Miscellaneous Outstanding Shares109,170,000Free Float99,891,000Market Cap$2.68 billion OptionableNot Optionable Beta1.41 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 61)CEO, Pres & Chairman Comp: $1.05MMr. Jack Anders (Age 46)Chief Financial Officer Comp: $544.8kMs. Margaret A. Horn J.D. (Age 60)Chief Operating Officer Comp: $775.6kDr. Stephen M. Kelsey FRC Path. (Age 62)FRCP, M.D., Pres of R&D Comp: $779kMs. Xiaolin Wang (Age 52)Exec. VP of Clinical Devel. Comp: $604.1kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 42)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsKrystal BiotechNASDAQ:KRYSDenali TherapeuticsNASDAQ:DNLIGinkgo BioworksNYSE:DNACRISPR TherapeuticsNASDAQ:CRSPImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsJeff CisliniSold 2,000 sharesTotal: $56,400.00 ($28.20/share)Barclays PLCBought 38,376 shares on 9/21/2023Ownership: 0.171%Stephen Michael KelseySold 2,060 sharesTotal: $64,498.60 ($31.31/share)Margaret A HornSold 2,514 sharesTotal: $78,713.34 ($31.31/share)Jack AndersSold 1,427 sharesTotal: $44,679.37 ($31.31/share)View All Insider TransactionsView All Institutional Transactions RVMD Stock - Frequently Asked Questions Should I buy or sell Revolution Medicines stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks. What is Revolution Medicines' stock price forecast for 2023? 7 analysts have issued 1-year price targets for Revolution Medicines' stock. Their RVMD share price forecasts range from $23.00 to $47.00. On average, they anticipate the company's stock price to reach $35.57 in the next twelve months. This suggests a possible upside of 45.0% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts. How have RVMD shares performed in 2023? Revolution Medicines' stock was trading at $23.82 at the beginning of the year. Since then, RVMD stock has increased by 3.0% and is now trading at $24.53. View the best growth stocks for 2023 here. When is Revolution Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our RVMD earnings forecast. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) posted its earnings results on Tuesday, August, 8th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.10. The company earned $3.82 million during the quarter, compared to analyst estimates of $1.56 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 36.46%. The business's revenue for the quarter was down 58.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.82) earnings per share. What ETFs hold Revolution Medicines' stock? ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL). When did Revolution Medicines IPO? (RVMD) raised $150 million in an initial public offering (IPO) on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. What is Revolution Medicines' stock symbol? Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD." How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Revolution Medicines' stock price today? One share of RVMD stock can currently be purchased for approximately $24.53. How much money does Revolution Medicines make? Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $2.68 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. How many employees does Revolution Medicines have? The company employs 292 workers across the globe. How can I contact Revolution Medicines? Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com. This page (NASDAQ:RVMD) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.